secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-01-24T23:59:59+00:00
Accession:  0001628280-25-002466
Event type: regulatory
Sentiment:  negative
Materiality: 0.35
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition
--------------------------------------------------------------------------------

- Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.
- Vacancy follows resignation of director Adam M. Koppel from board and audit committee effective Dec 29, 2024.
- Cure period runs until earlier of next annual meeting or Dec 29, 2025; if meeting before June 27, 2025, then by June 27, 2025.
- Board intends to appoint a new independent director to fill the audit committee vacancy within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/fhtx-20250123.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-002466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer